High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study (Q28364983)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study	scientific article

Statements

scholarly article

0 references

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study (English)

0 references

author name string

P H Cottu

1

0 references

J M Extra

2

0 references

M Espie

3

0 references

J P Marolleau

4

0 references

A de Roquancourt

5

0 references

J Makke

6

0 references

J M Miclea

7

0 references

V Laurence

8

0 references

D Mayeur

9

0 references

F Lerebours

10

0 references

C Cuvier

11

0 references

M Marty

12

0 references

language of work or name

0 references

publication date

2 November 2001

0 references

British Journal of Cancer

0 references

85

0 references

9

0 references

1240-6

0 references

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

30 October 2001

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Critique of the high-dose chemotherapy studies in breast cancer: a positive look at the data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

High-dose chemotherapy: is it standard management for any common solid tumor?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

29 September 2017

Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

2 June 2018

High-dose chemotherapy with autologous stem cell support for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

2 June 2018

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

2 June 2018

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2069

21 January 2018

A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2069

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1054%2FBJOC.2001.2069

21 January 2018

EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375253

27 November 2018

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast]

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy and breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11720455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2001.2069

0 references

Dimensions Publication ID

0 references

0 references

0 references

ResearchGate publication ID

0 references

Springer Nature article ID

10.1054/bjoc.2001.2069

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28364983&oldid=1883064471"